Abstract
Viral hepatitis is a serious public health problem due to the significant healthcare consequences of hepatitis-C (HCV) and hepatitis-B (HBV) in the United States. Since 2009, Food and Drug Administration (FDA) approved a new class of drugs for HCV and two new molecules for HBV. However, limited healthcare burden evidence exists for viral-hepatitis after the introduction of new drugs. Therefore, this study evaluated the marginal healthcare expenditures for viral-hepatitis using the Medical Expenditure Panel Survey (MEPS).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
